Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma : Notice Regarding Impairment Loss Following the Termination of DNA Vaccine ASP0892 Development

06/17/2021 | 03:02am EDT

Press Release

Notice Regarding Impairment Loss

Following the Termination of

DNA Vaccine ASP0892 Development

TOKYO, June 17, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced today that it has decided to terminate the development of the DNA vaccine ASP0892, which is currently in Phase 1 study for peanut allergy.

As a result of this termination, Astellas will book an impairment loss of ¥21.5 billion as other expenses in the first quarter of fiscal year 2021.

The impact from this termination is not reflected in Astellas' consolidated financial forecasts for the fiscal year ending March 31, 2022 announced in April 2021

1

About ASP0892

ASP0892 is the DNA vaccine using the LAMP-Vax platform, that was in-licensed from Immunomic Therapeutics, Inc.

About Astellas

Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at https://www.astellas.com/en.

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

###

Contacts for inquiries or additional information:

Astellas Pharma Inc.

Corporate Advocacy & Relations

TEL: +81-3-3244-3201

2

Disclaimer

Astellas Pharma Inc. published this content on 17 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 June 2021 07:01:01 UTC.


ę Publicnow 2021
All news about ASTELLAS PHARMA INC.
07/30ASTELLAS PHARMA : and Minovia Therapeutics Announce Strategic Collaboration for ..
BU
07/30Astellas and Minovia Therapeutics Announce Strategic Collaboration for Novel ..
CI
07/29ASTELLAS PHARMA : Presentation Material for Information Meeting (Q1/FY2021)
PU
07/29ASTELLAS PHARMA : Financial Results (Q1/FY2021)
PU
07/29ASTELLAS PHARMA : Supplementary Documents (Q1/FY2021)
PU
07/20The U.S. Food and Drug Administration Approves Astellas Pharma Inc.'s Supplem..
CI
07/15Piers Morgan rejoint le Conseil d'Administration de Pharnext
DJ
07/15Piers Morgan Joins Pharnext's Board of Directors
DJ
07/13ExCellThera and Astellas Enters into a License for the Use of Molecule UM171 ..
CI
07/12Affinivax and Astellas Presents Safety and Immunogenicity Data from Phase 2 S..
CI
More news
Financials
Sales 2022 1 323 B 12 058 M 12 058 M
Net income 2022 197 B 1 796 M 1 796 M
Net cash 2022 478 B 4 353 M 4 353 M
P/E ratio 2022 15,8x
Yield 2022 2,88%
Capitalization 3 222 B 29 360 M 29 373 M
EV / Sales 2022 2,07x
EV / Sales 2023 1,82x
Nbr of Employees 15 455
Free-Float 99,0%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 1 739,00 JPY
Average target price 2 459,23 JPY
Spread / Average Target 41,4%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Mamoru Sekiyama Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.9.10%29 360
JOHNSON & JOHNSON9.42%453 313
ROCHE HOLDING AG13.38%337 105
PFIZER, INC.16.30%239 637
NOVARTIS AG0.28%225 343
ELI LILLY AND COMPANY44.22%221 348